Drug profile · INN
hexylcaine hydrochloride
CYCLAINE
hexylcaine hydrochloride (CYCLAINE) is a sodium channel alpha subunit blocker. Route of administration: topical. Current US regulatory status: approved.
Drug details — hexylcaine hydrochloride
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
hexylcaine hydrochloride (CYCLAINE) is a sodium channel alpha subunit blocker. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is hexylcaine hydrochloride?
hexylcaine hydrochloride (CYCLAINE) is a sodium channel alpha subunit blocker. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for hexylcaine hydrochloride?
CYCLAINE is a marketed brand name for hexylcaine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of hexylcaine hydrochloride?
hexylcaine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.